Gene Modifying Immunotherapy for Blood Cancer Market, Global Outlook and Forecast 2022-2028

February 2022 | 60 pages | ID: G7E07022360FEN
Market Monitor Global

Abstracts

Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.

This report contains market size and forecasts of Gene Modifying Immunotherapy for Blood Cancer in Global, including the following market information:

Global Gene Modifying Immunotherapy for Blood Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Gene Modifying Immunotherapy for Blood Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

CAR T-cell Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gene Modifying Immunotherapy for Blood Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gene Modifying Immunotherapy for Blood Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Type, 2021 (%)

• CAR T-cell Therapy
• TCR T-cell Therapy

Global Gene Modifying Immunotherapy for Blood Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Application, 2021 (%)

• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• B Cell Lymphoma
• Multiple Myeloma
• Other

Global Gene Modifying Immunotherapy for Blood Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Gene Modifying Immunotherapy for Blood Cancer revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Gene Modifying Immunotherapy for Blood Cancer revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novartis
• Kite Pharma
• Juno Therapeutics
• Cellectis
• Ziopharm Oncology
• Celyad
• Bluebird Bio
• Bellicum Pharmaceuticals
• Mustang Bio

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Gene Modifying Immunotherapy for Blood Cancer Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL GENE MODIFYING IMMUNOTHERAPY FOR BLOOD CANCER OVERALL MARKET SIZE

2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size: 2021 VS 2028
2.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Gene Modifying Immunotherapy for Blood Cancer Players in Global Market
3.2 Top Global Gene Modifying Immunotherapy for Blood Cancer Companies Ranked by Revenue
3.3 Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Companies
3.4 Top 3 and Top 5 Gene Modifying Immunotherapy for Blood Cancer Companies in Global Market, by Revenue in 2021
3.5 Global Companies Gene Modifying Immunotherapy for Blood Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene Modifying Immunotherapy for Blood Cancer Players in Global Market
  3.6.1 List of Global Tier 1 Gene Modifying Immunotherapy for Blood Cancer Companies
  3.6.2 List of Global Tier 2 and Tier 3 Gene Modifying Immunotherapy for Blood Cancer Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Gene Modifying Immunotherapy for Blood Cancer Market Size Markets, 2021 & 2028
  4.1.2 CAR T-cell Therapy
  4.1.3 TCR T-cell Therapy
4.2 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue & Forecasts
  4.2.1 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2022
  4.2.2 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2023-2028
  4.2.3 By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Market Size, 2021 & 2028
  5.1.2 Acute Lymphocytic Leukemia
  5.1.3 Chronic Lymphocytic Leukemia
  5.1.4 B Cell Lymphoma
  5.1.5 Multiple Myeloma
  5.1.6 Other
5.2 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue & Forecasts
  5.2.1 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2022
  5.2.2 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2023-2028
  5.2.3 By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Market Size, 2021 & 2028
6.2 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue & Forecasts
  6.2.1 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2022
  6.2.2 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2023-2028
  6.2.3 By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028
  6.3.2 US Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.3.3 Canada Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.3.4 Mexico Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028
  6.4.2 Germany Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.4.3 France Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.4.4 U.K. Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.4.5 Italy Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.4.6 Russia Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.4.7 Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.4.8 Benelux Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028
  6.5.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.5.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.5.4 South Korea Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.5.5 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.5.6 India Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028
  6.6.2 Brazil Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.6.3 Argentina Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028
  6.7.2 Turkey Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.7.3 Israel Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.7.4 Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028
  6.7.5 UAE Gene Modifying Immunotherapy for Blood Cancer Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis
  7.1.1 Novartis Corporate Summary
  7.1.2 Novartis Business Overview
  7.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.1.4 Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.1.5 Novartis Key News
7.2 Kite Pharma
  7.2.1 Kite Pharma Corporate Summary
  7.2.2 Kite Pharma Business Overview
  7.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.2.4 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.2.5 Kite Pharma Key News
7.3 Juno Therapeutics
  7.3.1 Juno Therapeutics Corporate Summary
  7.3.2 Juno Therapeutics Business Overview
  7.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.3.4 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.3.5 Juno Therapeutics Key News
7.4 Cellectis
  7.4.1 Cellectis Corporate Summary
  7.4.2 Cellectis Business Overview
  7.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.4.4 Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.4.5 Cellectis Key News
7.5 Ziopharm Oncology
  7.5.1 Ziopharm Oncology Corporate Summary
  7.5.2 Ziopharm Oncology Business Overview
  7.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.5.4 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.5.5 Ziopharm Oncology Key News
7.6 Celyad
  7.6.1 Celyad Corporate Summary
  7.6.2 Celyad Business Overview
  7.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.6.4 Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.6.5 Celyad Key News
7.7 Bluebird Bio
  7.7.1 Bluebird Bio Corporate Summary
  7.7.2 Bluebird Bio Business Overview
  7.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.7.4 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.7.5 Bluebird Bio Key News
7.8 Bellicum Pharmaceuticals
  7.8.1 Bellicum Pharmaceuticals Corporate Summary
  7.8.2 Bellicum Pharmaceuticals Business Overview
  7.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.8.4 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.8.5 Bellicum Pharmaceuticals Key News
7.9 Mustang Bio
  7.9.1 Mustang Bio Corporate Summary
  7.9.2 Mustang Bio Business Overview
  7.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Major Product Offerings
  7.9.4 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue in Global Market (2017-2022)
  7.9.5 Mustang Bio Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Gene Modifying Immunotherapy for Blood Cancer Market Opportunities & Trends in Global Market
Table 2. Gene Modifying Immunotherapy for Blood Cancer Market Drivers in Global Market
Table 3. Gene Modifying Immunotherapy for Blood Cancer Market Restraints in Global Market
Table 4. Key Players of Gene Modifying Immunotherapy for Blood Cancer in Global Market
Table 5. Top Gene Modifying Immunotherapy for Blood Cancer Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Companies, 2017-2022
Table 8. Global Companies Gene Modifying Immunotherapy for Blood Cancer Product Type
Table 9. List of Global Tier 1 Gene Modifying Immunotherapy for Blood Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gene Modifying Immunotherapy for Blood Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
Table 30. Novartis Corporate Summary
Table 31. Novartis Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 32. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 33. Kite Pharma Corporate Summary
Table 34. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 35. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 36. Juno Therapeutics Corporate Summary
Table 37. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 38. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 39. Cellectis Corporate Summary
Table 40. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 41. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 42. Ziopharm Oncology Corporate Summary
Table 43. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 44. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 45. Celyad Corporate Summary
Table 46. Celyad Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 47. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 48. Bluebird Bio Corporate Summary
Table 49. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 50. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 51. Bellicum Pharmaceuticals Corporate Summary
Table 52. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 53. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
Table 54. Mustang Bio Corporate Summary
Table 55. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product Offerings
Table 56. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Gene Modifying Immunotherapy for Blood Cancer Segment by Type in 2021
Figure 2. Gene Modifying Immunotherapy for Blood Cancer Segment by Application in 2021
Figure 3. Global Gene Modifying Immunotherapy for Blood Cancer Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2021
Figure 8. By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 9. By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 10. By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 11. By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 12. US Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 16. Germany Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 17. France Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 24. China Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 28. India Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 30. Brazil Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
Figure 33. Turkey Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
Figure 37. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)